Confronto
Cagrilintide vs. Ecnoglutide
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Metabolico
Metabolico
N. CAS
1415456-99-3
nessun dato
Peso molecolare
4253.7 g/mol
nessun dato
Emivita
168 h
144 h
Sequenza
KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTYnessun dato
Meccanismo d'azione
Cagrilintide
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
Ecnoglutide
Ecnoglutide is a modified GLP-1(7-37) peptide with an alanine-to-valine substitution at position 8 and an 18-C fatty-acid conjugation at the lysine-30 side chain. It is a so-called biased agonist: at the GLP-1 receptor it preferentially induces cAMP formation while β-arrestin recruitment is reduced. In preclinical models this has been linked to lower receptor internalisation and desensitisation. GLP-1 receptor activation is mechanistically associated with enhanced glucose-dependent insulin secretion, delayed gastric emptying and satiety signalling. The fatty-acid conjugation enables weekly administration via albumin binding.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
4
5
di cui sull'uomo
3
5
Effetti registrati
3
4
Contraddizioni aperte
1
0
Eventi avversi documentati
1
1
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Cagrilintide and Ecnoglutide?
- Cagrilintide is classified as "Metabolico", while Ecnoglutide is classified as "Metabolico". Cagrilintide: Synthetic long-acting amylin analog being developed in combination with semaglutide (CagriSema). Phase 3 trials for obesity and type 2 diabetes are ongoing. No marketing approval yet. Ecnoglutide: Ecnoglutide (XW003) is a long-acting, cAMP-signalling-biased GLP-1 analogue from Sciwind Biosciences. Derived from GLP-1(7-37) with an alanine-to-valine substitution at position 8, it activates the GLP-1 receptor selectively via the cAMP pathway over β-arrestin recruitment. Investigated for weight management and in type 2 diabetes. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Cagrilintide or Ecnoglutide?
- The highest available evidence level is "RCT sull'uomo" for Cagrilintide and "RCT sull'uomo" for Ecnoglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Cagrilintide and Ecnoglutide in Germany and the United States?
- Germania: Cagrilintide — Non approvato, Ecnoglutide — Non approvato. Stati Uniti: Cagrilintide — Non approvato, Ecnoglutide — Non approvato. These are factual summaries with source and review date on the individual pages.